Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
Sponsor: Lisata Therapeutics, Inc.
Summary
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.
Official title: A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
34
Start Date
2020-10-29
Completion Date
2022-09-28
Last Updated
2026-05-04
Healthy Volunteers
No
Conditions
Interventions
CLBS16
GCSF-mobilized autologous CD34+ cells
Placebo
isotonic solution (no CD34+ cells)
Locations (7)
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of Florida - College of Medicine/ div of Cardiovascular Medicine
Gainesville, Florida, United States
Memorial Regional Hospital
Hollywood, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Minneapolis Heart Institute at Abbott Northwestern Hospital
Minneapolis, Minnesota, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
The Christ Hospital
Cincinnati, Ohio, United States